Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Vectus Biosystems Limited ( (AU:VBS) ) is now available.
Vectus Biosystems Limited announced its half-year financial results, revealing a 39% decline in income from ordinary activities, amounting to $393,707. The net loss after tax for the period decreased by 7% to $1,099,959. No dividends were declared for the period. The net tangible assets per share significantly dropped from 4.45 cents to 0.76 cents, indicating a potential challenge in financial stability. These results may impact the company’s operational strategies and its standing in the biotechnology market.
More about Vectus Biosystems Limited
Vectus Biosystems Limited operates within the biotechnology sector, focusing on developing and commercializing therapeutic products. The company primarily targets diseases related to fibrosis and high blood pressure, aiming to address significant unmet medical needs in these areas.
YTD Price Performance: -6.25%
Average Trading Volume: 22,126
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$4.26M
Find detailed analytics on VBS stock on TipRanks’ Stock Analysis page.